Yahoo! Finance: Biotechnology Industry News: New Data Analyses Show Significant Clinical and MRI Improvements with PLEGRIDY™ (Peginterferon Beta-1a)

Yahoo! Finance: Biotechnology Industry News The latest news on the Biotechnology industry from Yahoo! Finance

The Next Generation in Online Meetings GoTo Webinar is a new, affordable, do-it-yourself Web event service that doesn't require a consultant. Get $10 off after your complimentary trial. From our sponsors

New Data Analyses Show Significant Clinical and MRI Improvements with PLEGRIDY™ (Peginterferon Beta-1a) Oct 1st 2013, 06:30 [Business Wire] - Biogen Idec announced new data analyses from year one of the two-year, pivotal, Phase 3 ADVANCE study of PLEGRIDYTM . PLEGRIDY is an investigational subcutaneous injectable for relapsing forms of multiple sclerosis , in which interferon beta-1a is pegylated to prolong the molecule's exposure in the body and enable the study of a less frequent dosing schedule.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions